Meksibel

Phase 1Small molecule

VVitebsk State Medical University

Meksibel is one of 38 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Acute PancreatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

69 competitors in Acute Pancreatitis

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Approved

1 2

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Approved

1 3

VIOKACE

DDigestive Care, Inc.

Approved

1 4

Advil

Zocor

Relistor

Octreotide

1 8

Balanced Crystalloid

SSeoul National University Hospital

Approved

1 9

Indocin

LLife Extension Foundation Inc.

Phase 3

3 10

Trental

VValidus Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Pancreatitis1 trial

Prevention of Acute Pancreatitis After Endoscopic Interventions

Unknown status·VVitebsk State Medical University·Phase 1·NCT04608760·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meksibel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meksibel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meksibel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vitebsk State Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVitebsk State Medical University

Meksibel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News